

CITATION REPORT

List of articles citing

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort

DOI: 10.1002/hep.20636
Hepatology, 2005, 41, 707-16.

Source: <https://exaly.com/paper-pdf/38329774/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
546	Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. 2005 , 9, 1207-15; discussion 1215		188
545	Comparison of staging systems for HCC: one more positive answer or mission impossible?. <i>Hepatology</i> , 2005 , 42, 238-9	11.2	5
544	Reactivation of viral replication after replacement of tenofovir by adefovir. <i>Hepatology</i> , 2005 , 42, 239-40	11.2	15
543	Staging of hepatocellular carcinoma. <i>Hepatology</i> , 2005 , 42, 738-9; author reply 739-40	11.2	4
542	Reply:. <i>Hepatology</i> , 2005 , 42, 739-740	11.2	2
541	Management of hepatocellular carcinoma. <i>Hepatology</i> , 2005 , 42, 1208-36	11.2	4778
540	Hepatocellular carcinoma: current treatment strategies. 2005 , 8, 457-66		9
539	Prognostic prediction in patients with hepatocellular carcinoma. 2005 , 25, 171-80		71
538	Early detection and curative treatment of early-stage hepatocellular carcinoma. 2005 , 3, S144-8		37
537	Should we expand the criteria for liver transplantation for hepatocellular carcinoma--yes, of course!. 2005 , 43, 569-73		48
536	Hepatocellular carcinoma: overcoming challenges in disease management. 2006 , 4, 252-61		48
535	Hepatocellular carcinoma. 2006 , 10, 339-51, ix		26
534	Prospective validation of the Barcelona Clinic Liver Cancer staging system. 2006 , 44, 723-31		323
533	Staging systems for hepatocellular carcinoma: should we all use the BCLC system?. 2006 , 44, 630-2		24
532	Current World Literature. 2006 , 11, 311-350		
531	Hepatocellular carcinoma. 2006 , 22, 248-53		84
530	Bibliography. Current world literature. Liver and biliary tract. 2006 , 22, 305-39		

529	Treatment and prognostic factors in patients with hepatocellular carcinoma. 2006 , 26, 680-7	42
528	Comparison of staging systems to predict survival in hepatocellular carcinoma. 2006 , 26, 673-9	21
527	Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. 2006 , 24, 573-83	60
526	New aspects of diagnosis and therapy of hepatocellular carcinoma. 2006 , 25, 3848-56	125
525	Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. 2006 , 41, 250-6	39
524	What is the best staging system for hepatocellular carcinoma?. 2006 , 41, 290-1	1
523	[Recurrent disease after liver transplantation. A therapeutic dilemma or treatable?]. 2006 , 101, 939-50	2
522	Treatment of hepatocellular carcinoma. 2006 , 60, 89-98	123
521	Waiting list removal rates among patients with chronic and malignant liver diseases. 2006 , 6, 1416-21	163
520	Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. 2006 , 203, 426-35	78
519	The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. 2006 , 107, 141-8	52
518	Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. 2006 , 12, 912-9	73
517	Therapie des hepatozellulären Karzinoms. 2006 , 27, 171-177	
516	[Treatment of hepatocellular carcinoma]. <i>Zeitschrift Fur Gastroenterologie</i> , 2006 , 44, 43-9	1.6 8
515	Liver and Biliary Tract Surgery. 2006 ,	4
514	Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. 2006 , 101, 975-82	45
513	The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. 2007 , 102, 1920-30	56
512	[The diagnostic approach to hepatocellular carcinoma]. <i>Zeitschrift Fur Gastroenterologie</i> , 2007 , 45, 1067-74	4

511	Anatomie der Leber und Pathologie der Lebertumoren. 2007 , 42, 215-222		
510	Enhancing and expansile portal vein thrombosis: value in the diagnosis of hepatocellular carcinoma in patients with multiple hepatic lesions. 2007 , 188, 1320-3		72
509	Aktuelle Diagnostik und Therapie des hepatozellulären Karzinoms. 2007 , 3, 115-132		
508	Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. 2007 , 83, 893-9		115
507	Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. <i>European Journal of Surgical Oncology</i> , 2007 , 33, 480-7	3.6	30
506	Predicting survival in patients with hepatocellular carcinoma: a UK perspective. <i>European Journal of Surgical Oncology</i> , 2007 , 33, 188-94	3.6	9
505	Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. 2007 , 47, 527-37		189
504	The use of imaging in the diagnosis and staging of hepatobiliary malignancies. 2007 , 16, 343-68		40
503	Epidemiology and outcome of hepatocellular carcinoma in Lombardy. 2007 , 39, 1011-7		10
502	Modified Charlson comorbidity index for predicting survival after liver transplantation. 2007 , 13, 1515-20		110
501	Clinical and molecular classification of hepatocellular carcinoma. 2007 , 13, S13-6		16
500	Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. 2007 , 96, 477-84		75
499	Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. 2007 , 204, 1016-27; discussion 1027-8		67
498	Review of current staging systems for hepatocellular carcinoma. 2007 , 37 Suppl 2, S210-5		7
497	International comparison of treatment outcomes based on staging systems. 2007 , 37 Suppl 2, S216-22		4
496	Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. 2007 , 30, 6-25		599
495	Improving clinical trial design for hepatocellular carcinoma treatments. 2007 , 1, 45-52		1
494	Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. 2008 , 17, 831-43		48

493	Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulären Karzinoms. 2008 , 1, 109-119	
492	Early detection of liver cancer: diagnosis and management. 2008 , 10, 60-6	17
491	Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. 2008 , 112, 352-61	101
490	Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma. 2008 , 41, 1131-9	22
489	Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. 2008 , 15, 2153-63	95
488	Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. 2008 , 23, 445-52	40
487	Management and patient survival in hepatocellular carcinoma: does the physician's level of experience matter?. 2008 , 23, e179-88	11
486	Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. 2008 , 23, 1267-75	10
485	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. 2008 , 23, 1259-66	29
484	Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. 2008 , 28, 62-75	64
483	[Liver transplant in patients with hepatocellular carcinoma]. 2008 , 84, 117-24	3
482	A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. 2008 , 206, 281-91	98
481	Diagnosis and treatment of hepatocellular carcinoma. 2008 , 134, 1752-63	842
480	Novel advancements in the management of hepatocellular carcinoma in 2008. 2008 , 48 Suppl 1, S20-37	635
479	Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). 2008 , 44, 528-38	78
478	The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. 2008 , 44, 1000-6	163
477	Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?. <i>European Journal of Surgical Oncology</i> , 2008 , 34, 256-62	3.6 46
476	Hepatocellular carcinoma. 2008 , 54, 432-44	9

475	MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. 2008 , 247, 311-30	303
474	Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. 2008 , 19, 1117-26	64
473	Advances in prevention and diagnosis of hepatocellular carcinoma. 2008 , 2, 425-33	8
472	Design and endpoints of clinical trials in hepatocellular carcinoma. 2008 , 100, 698-711	1360
471	Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. 2008 , 103, 597-604	94
470	Targeting vessels to treat hepatocellular carcinoma. 2008 , 114, 467-77	6
469	Staging Systems for Hepatocellular Carcinoma. 107-114	
468	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. 2008 , 20, 444-53	51
467	Evolving therapies in the treatment of hepatocellular carcinoma. 2008 , 2, 453-62	13
466	Staging of hepatocellular carcinoma. 51-56	
465	Systemic therapies for advanced hepatocellular carcinoma. 97-121	
464	Hepatocellular carcinoma in Keio affiliated hospitals--diagnosis, treatment, and prognosis of this disease. 2009 , 58, 161-75	6
463	Multimodal approaches to the treatment of hepatocellular carcinoma. 2009 , 6, 159-69	59
462	Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. 2009 , 1, 48-61	12
461	Clinical staging of hepatocellular carcinoma. 2009 , 27, 131-41	14
460	Hepatocellular Carcinoma. 2009 ,	
459	Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. 2009 , 15, 4686-93	78
458	Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. 2009 , 131, 498-510	102

457	[Hepatocellular carcinoma management in the era of sorafenib]. 2009 , 33, 327-33		
456	Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. <i>Hepatology</i> , 2009 , 50, 1839-50	11.2	106
455	Liberal selection criteria for liver transplantation for hepatocellular carcinoma. 2009 , 96, 785-91		21
454	Perioperative risk assessment for hepatocellular carcinoma by using the MELD score. 2009 , 13, 2268-75		25
453	Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. 2009 , 30, 37-47		549
452	Comparative performances of staging systems for early hepatocellular carcinoma. 2009 , 11, 382-90		22
451	Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. 2009 , 29, 502-10		234
450	The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. 2009 , 73, 1155-63		66
449	Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. 2009 , 45, 1630-9		62
448	Hepatocellular carcinoma and liver transplantation: a 12-year experience. 2009 , 41, 1005-8		16
447	[Diagnosis and treatment of hepatocellular carcinoma]. 2009 , 132, 272-87		37
446	A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. 2009 , 41, 431-41		31
445	Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. 2009 , 28, 142		4
444	Major achievements in hepatocellular carcinoma. 2009 , 373, 614-6		244
443	Current management of hepatocellular carcinoma. 2009 , 93, 885-900, viii		45
442	Modern diagnosis and management of hepatocellular carcinoma. 2009 , 13, 233-47		34
441	Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems. 2009 , 43, 773-81		18
440	NCCN clinical practice guidelines in oncology: hepatobiliary cancers. 2009 , 7, 350-91		390

439	Recent advances in the treatment of hepatocellular carcinoma. 2010 , 26, 189-95	34
438	Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. 2010 , 17, 120-9	32
437	Interventional radiological treatment of hepatocellular carcinoma. 2010 , 17, 87-99	15
436	Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice?. 2010 , 34, 2155-61	71
435	Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: imaging diagnosis and staging of hepatocellular carcinoma. 2010 , 17, 369-73	45
434	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. 2009 , 4, 396-405	31
433	Current management of hepatocellular cancer. 2010 , 12, 186-92	39
432	Pre-operative nomogram to predict risk of peri-operative mortality following liver resections for malignancy. 2010 , 14, 1770-81	14
431	[Hepatocellular carcinoma: diagnosis, staging, and treatment strategy]. 2010 , 52, 385-98	7
430	Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. 2010 , 10, 620	4
429	Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. 2010 , 116, 3006-14	80
428	Drug therapy: sorafenib. <i>Hepatology</i> , 2010 , 51, 1843-9	11.2 18
427	Inherited hepatocellular carcinoma. 2010 , 24, 725-34	17
426	Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. 2010 , 12, 289-99	135
425	Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. 2010 , 101, 1314-9	44
424	Review article: the management of hepatocellular carcinoma. 2010 , 31, 461-76	158
423	Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. 2010 , 17, 6-12	6
422	An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. 2010 , 24, 643-50	28

421	The challenge of prognosis and staging for hepatocellular carcinoma. 2010 , 15 Suppl 4, 23-33	106
420	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. 2010 , 56, e1-48	160
419	Advanced hepatocellular carcinoma: which staging systems best predict prognosis?. 2010 , 28, 2889-95	242
418	Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?. 2010 , 15 Suppl 4, 42-52	121
417	Disparities in hepatocellular carcinoma survival among Californians of Asian ancestry, 1988 to 2007. 2010 , 19, 2747-57	33
416	Developing better treatments in hepatocellular carcinoma. 2010 , 4, 551-60	20
415	Current strategy for staging and treatment: the BCLC update and future prospects. 2010 , 30, 61-74	770
414	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. 2010 , 42 Suppl 3, S258-63	46
413	Future perspectives in hepatocellular carcinoma. 2010 , 42 Suppl 3, S302-9	55
412	Hepatocellular Carcinoma: Diagnosis, staging, and treatment strategy. 2010 , 52, 385-398	5
411	Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail. 2010 , 53, 23-4	6
410	Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems. <i>European Journal of Surgical Oncology</i> , 2010 , 36, 718-24	3.6 28
409	The model of end-stage liver disease (MELD) score in predicting postoperative liver failure after hepatic resection of hepatocellular carcinoma in cirrhotic patients: The Tunisian experience. 2010 , 11, 35-38	
408	Epidemiology and management of hepatocellular carcinoma. 2010 , 24, 899-919, viii	131
407	Locoregional therapy for hepatocellular carcinoma. 2011 , 15, 395-421, vii-x	14
406	Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. 2011 , 140, 1501-12.e2	307
405	Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. 2011 , 43, 319-24	19
404	Targeted therapies for hepatocellular carcinoma. 2011 , 140, 1410-26	360

403	Level of α -fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. 2011 , 9, 989-94		39
402	NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. 2011 , 310, 35-45		93
401	Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. 2011 , 47, 2568-75		50
400	Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. 2011 , 18, 228-40		44
399	Hepatocellular carcinoma: current management and perspectives for the future. 2011 , 253, 453-69		333
398	Personalized medicine in hepatocellular carcinoma: rationale and clinical data. 2011 , 1, 1403-1411		1
397	Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. 2011 , 45, 727-32		64
396	Treatment options in hepatocellular carcinoma today. 2011 , 100, 22-9		83
395	Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells. 2011 , 26, 1581-6		9
394	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. 2011 , 26, 340-7		64
393	Presentation and outcomes of hepatocellular carcinoma patients at a western centre. 2011 , 13, 712-22		22
392	Inhibiting TGF- β signaling in hepatocellular carcinoma. 2011 , 1815, 214-23		49
391	Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. 2011 , 18, 1964-71		47
390	A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 739-50	4.9	40
389	Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis. 2011 , 42, 228-35		5
388	What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?. 2011 , 17 Suppl 2, S26-33		15
387	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. <i>Hepatology</i> , 2011 , 54, 868-78	11.2	458
386	Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. 2011 , 16, 1258-69		78

385	A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. 2011 , 16, 310-8	29
384	Hepatocellular carcinoma: focus on different aspects of management. 2012 , 2012, 421673	70
383	Tumours and tumour-like lesions of the liver. 2012 , 761-851	19
382	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. <i>Hepatic Medicine: Evidence and Research</i> , 2012 , 4, 19-37	3-4 151
381	Multimodality treatment with conventional transcatheter arterial chemoembolization and radiofrequency ablation for unresectable hepatocellular carcinoma. 2012 , 85, 18-26	7
380	Assessment of preoperative magnetic resonance imaging staging in patients with hepatocellular carcinoma undergoing resection compared with the seventh American Joint Committee on Cancer System. 2012 , 47, 634-41	11
379	Management of HCC. 2012 , 56 Suppl 1, S75-87	438
378	Diagnostik und Früherkennung des hepatozellulären Karzinoms. 2012 , 7, 390-397	
377	Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. 2012 , 87, 9-16	33
376	Hepatocellular Carcinoma. 2012 , 1005-1031	1
375	Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. 2012 , 32, 1120-7	83
374	Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. 2012 , 203, 741-50	33
373	Back to basics: staging and prognosis in HCC for medical oncologist. 2012 , 56, 488-9	6
372	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012 , 56, 908-43	4465
371	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. 2012 , 56, 1080-1088	88
370	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. 2012 , 57, 821-9	589
369	A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). 2012 , 57, 1013-20	146
368	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. 2012 , 48, 1452-65	197

367	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012 , 48, 599-641	356
366	Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. 2012 , 81, 466-71	45
365	[Genomic prognostic markers in hepatocellular carcinoma]. 2012 , 35, 94-101	2
364	Primary Hepatic Cancer. 2012 , 161-181	
363	BCLC treatment algorithm and the place of selective internal radiation therapy. 2012 , 10, 27-29	
362	Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area. 2012 , 36, 357-64	1
361	Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. 2012 , 83, 216-24	37
360	Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization. 2012 , 10, e83-4	
359	Systemtherapie des Leberzellkarzinoms. 2012 , 15, 26-30	
358	Primary Liver Cancer. 2012 ,	1
357	The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. 2012 , 104, 298-304	29
356	Quantitative portal vein velocity of liver cancer patients with transcatheter arterial chemoembolization on angiography. 2012 , 2012, 830531	3
355	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. <i>Hepatology</i> , 2012 , 56, 614-21	11.2 67
354	Tumors of the liver: Pathologic aspects. 2012 , 1223-1249.e5	2
353	Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study. 2012 , 6, 505-10	8
352	Hepatocellular carcinoma: MR staging and therapeutic decisions. 2012 , 37, 231-8	1
351	Is there any benefit from expanding the criteria for the resection of hepatocellular carcinoma in cirrhotic liver? Experience from a developing country. 2012 , 36, 1657-65	12
350	Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 1121-9	4.9 61

349	Risk factors of early re-bleeding and mortality in patients with ruptured gastric varices and concomitant hepatocellular carcinoma. 2012 , 47, 531-9		7
348	Systemtherapie des Leberzellkarzinoms. 2012 , 18, 602-610		
347	A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. 2012 , 36, 551-9		11
346	Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. 2013 , 2, 37		31
345	Consensus report of the Fifth International Forum for Liver MRI. 2013 , 201, 97-107		35
344	Multidisciplinary Treatment of Hepatocellular Carcinoma. 2013 ,		2
343	Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 635-43	4.9	26
342	The size of the problem: clinical algorithms. 2013 , 31, 95-103		5
341	Hepatocellular carcinoma: illustrated guide to systematic radiologic diagnosis and staging according to guidelines of the American Association for the Study of Liver Diseases. 2013 , 33, 1653-68		69
340	Advanced precancerous lesions in the liver. 2013 , 27, 269-84		42
339	Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. <i>Hepatology</i> , 2013 , 57, 112-9	11.2	132
338	The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. 2013 , 45, 408-13		28
337	HBV infection and hepatocellular carcinoma. 2013 , 17, 375-97		33
336	Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh A cirrhosis: is clinical evidence of portal hypertension a contraindication?. 2013 , 15, 78-84		105
335	Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy. 2013 , 34, 1061-70		6
334	A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. 2013 , 145, 176-187		254
333	A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 1709-19	4.9	18
332	The role of liver cancer stem cells in donor liver allocation for patients with hepatocellular carcinoma. 2013 , 125, 24-30		1

331	Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. 2012 , 32, 348-59		387
330	Multidisciplinary management of hepatocellular carcinoma: where are we today?. 2013 , 33 Suppl 1, S3-10		28
329	Multidisciplinary approach for HCC patients: hepatology for the oncologists. 2013 , 24 Suppl 2, ii15-23		23
328	Recent advances in the treatment of hepatocellular carcinoma. 2013 , 29, 285-92		80
327	Hepatocellular carcinoma: perspective of an oncologist. 2013 , 47 Suppl, S47-9		
326	Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. 2013 , 19, 3944-54		93
325	Portal stenting for hepatocellular carcinoma extending into the portal vein in cirrhotic patients. 2013 , 107, 696-701		11
324	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 639-51	2.2	27
323	A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. 2013 , 257, 929-37		337
322	Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. 2013 , 28, 213-9		30
321	Surgical Management of Primary Hepatocellular Carcinoma. 2013 ,		
320	Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. 2014 , 9, e90929		51
319	Prognosis of patients with hepatocellular carcinoma and hypersplenism after surgery: a single-center experience from the People's Republic of China. <i>OncoTargets and Therapy</i> , 2014 , 7, 957-64 ^{4.4}		6
318	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. 2014 , 13, S4-S40		17
317	m-RECIST at 1 month and Child A are survival predictors after percutaneous ethanol injection of hepatocellular carcinoma. 2014 , 13, 796-802		2
316	Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. 2014 , 110, 2090-8		32
315	Mexican consensus on the diagnosis and management of hepatocellular carcinoma. 2014 , 79, 250-262		
314	The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. <i>Cancers</i> , 2014 , 6, 79-111	6.6	53

313	The addition of C-reactive protein to validated staging systems improves their prognostic ability in patients with hepatocellular carcinoma. 2014 , 86, 308-17	16
312	Mexican consensus on the diagnosis and management of hepatocellular carcinoma. 2014 , 79, 250-62	10
311	Overexpression of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 (LGR5) Represents a Typical Wnt/ β Catenin Pathway-Activated Hepatocellular Carcinoma. 2014 , 3, 451-7	10
310	Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. 2014 , 29, 787-93	45
309	Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. 2014 , 34, 1109-17	15
308	Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. 2014 , 34, 612-20	15
307	Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas. 2014 , 122, 1001-6	4
306	Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. 2014 , 8, 71-6	105
305	Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?. 2014 , 93, e180	46
304	Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. 2014 , 146, 1691-700.e3	425
303	Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. 2014 , 59, 192-200	24
302	A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. 2014 , 34, 194-203	62
301	Staging of biliary tract and primary liver tumors. 2014 , 23, 313-22	7
300	Variceal Hemorrhage. 2014 ,	2
299	Hepatocellular carcinoma and other liver lesions. 2014 , 98, 103-18	14
298	Reassessing hepatocellular carcinoma staging in a changing patient population. 2014 , 86, 63-71	1
297	Treatment of intermediate-stage hepatocellular carcinoma. 2014 , 11, 525-35	315
296	Hepatocellular carcinoma. 2014 , 164, 450-5	17

295	How grim is hepatocellular carcinoma?. 2014 , 3, 71-6		15
294	Prognosis prediction and staging. 2014 , 28, 855-65		15
293	The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. 2014 , 184, 574-83		63
292	Treatment algorithms for managing hepatocellular carcinoma. 2014 , 4, S80-9		48
291	Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. 2014 , 25, 1056-66		19
290	Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. 2014 , 9, e103228		23
289	A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. 2014 , 93, e348		14
288	Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors. 2015 , 106, 611-7		20
287	Hepatocellular Carcinoma. 2015 , 2146-2165		
286	Evaluation of eight different clinical staging systems associated with overall survival of chinese patients with hepatocellular carcinoma. 2015 , 128, 316-21		11
285	A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer. <i>OncoTargets and Therapy</i> , 2015 , 8, 1375-85	4-4	56
284	Staging systems for hepatocellular carcinoma: Current status and future perspectives. 2015 , 7, 406-24		84
283	Polymorphisms in Genes of Tricarboxylic Acid Cycle Key Enzymes Are Associated with Early Recurrence of Hepatocellular Carcinoma. 2015 , 10, e0124471		3
282	Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. 2015 , 52 Suppl 1, 2-14		10
281	Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma. 2015 , 2015, 687484		4
280	Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. 2015 , 6, 4440-50		54
279	New challenges in clinical research on hepatocellular carcinoma. 2016 , 108, 485-93		11
278	Diagnostic and therapeutic management of hepatocellular carcinoma. 2015 , 21, 12003-21		53

277	Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. 2015 , 21, 10327-35		79
276	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. 2015 , 12, 408-24		318
275	Cost-utility analysis of nonalcoholic steatohepatitis screening. 2015 , 25, 3282-94		35
274	Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients. 2015 , 94, e1929		29
273	The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan. 2015 , 94, e1659		4
272	Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma. 2015 , 94, e1486		38
271	Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. 2015 , 3, 284-93		4
270	Proposal of the performance status combined Japan Integrated Staging system in hepatocellular carcinoma complicated with cirrhosis. 2015 , 46, 2371-9		8
269	In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?. 2015 , 35, 627-35		66
268	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. 2015 , 62, 617-24		129
267	Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. 2015 , 30, 696-705		11
266	A retrospective analysis of cirrhotic patients receiving Chinese herbal medicine in addition to conventional care: Survival and safety. 2015 , 7, 143-150		5
265	New molecular therapies for hepatocellular carcinoma. 2015 , 39 Suppl 1, S80-5		27
264	Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification?. 2015 , 2, 245-253		3
263	Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoembolization. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 1153-61	3.6	49
262	Hepatoma Research: the beginning of a new forum. 2015 , 1, 1		1
261	Treatment of Liver Cancer. 2015 , 5, a021535		144
260	Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making. 2015 , 19, 277-94		16

259	Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. 2015 , 62, 855-62	100
258	Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience. 2015 , 60, 1465-73	10
257	Addressing the interplay of liver disease and hepatocellular carcinoma on patient survival: the ALBI scoring model. 2015 , 33, 529-31	13
256	Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma. 2015 , 22 Suppl 3, S1075-82	18
255	Livin is associated with the invasive and oncogenic phenotypes of human hepatocellular carcinoma cells. 2015 , 45, 448-57	9
254	Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. 2016 , 8, 703-15	21
253	Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience. 2016 , 2016, 1989045	14
252	Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study. 2016 , 16, 424	10
251	Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. 2016 , 34, 160-167	55
250	Circulating CD147 predicts mortality in advanced hepatocellular carcinoma. 2016 , 31, 459-66	13
249	Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. 2016 , 39, 428-32	15
248	BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. 2016 , 31, 467-74	35
247	MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. <i>Hepatology</i> , 2016 , 63, 1227-39	11.2 17
246	Computer-aided diagnosis for estimating the malignancy grade of hepatocellular carcinoma using contrast-enhanced ultrasound: an ROC observer study. 2016 , 36, 1026-32	13
245	A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. 2016 , 36, 1821-1828	63
244	Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. 2016 , 31, 842-7	17
243	Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study. 2016 , 95, e3527	21
242	Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma. 2016 , 7, e172	16

241	An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway. 2016 , 376, 188-96	51
240	Management of Hepatocellular Carcinoma (HCC). 2016 , 4, 1	5
239	Does Karnofsky Performance Status of Patients With Cirrhosis on the Transplant Waitlist Meet the Eyeball Test?. 2016 , 14, 1196-8	13
238	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. 2016 , 17, 1923-36	12
237	Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute. 2016 , 3, 162-71	19
236	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. 2016 , 146, 511.e1-511.e22	1
235	Prognostic value of polarized macrophages in patients with hepatocellular carcinoma after curative resection. 2016 , 20, 1024-35	27
234	Comparison of hepatocellular carcinoma in Eastern versus Western populations. 2016 , 122, 3430-3446	150
233	Cancer Epidemiology Among Asian Americans. 2016 ,	1
232	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. 2016 , 63, 25-33	34
231	Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. 2016 , 31, 1300-6	83
230	Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. 2016 , 36, 1498-506	22
229	SNF5 is Involved in Suppression of Hepatocellular Carcinoma Progression via TGF-Beta 1 Signaling. 2016 , 299, 869-77	6
228	Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. 2016 , 65, 861-9	136
227	Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. 2016 , 4, 515-522	3
226	Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. 2016 , 7, 32-35	8
225	[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. 2016 , 146, 511.e1-511.e22	36
224	Long-Term Outcomes of Liver Resection. 2016 , 95-103	

223	Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. 2016 , 64, 601-8		162
222	Clinical implications of basic research in hepatocellular carcinoma. 2016 , 64, 736-45		31
221	Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. 2016 , 65, 1035-41		114
220	Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. 2017 , 32, 221-228		39
219	Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy. 2017 , 89, 153-160		5
218	Is the Hong Kong Liver Cancer Staging System Ready to Replace the Barcelona Clinic Liver Cancer System?. 2017 , 15, 756-758		1
217	Effect of Age (over 75 Years) on Postoperative Complications and Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. 2017 , 21, 657-665		11
216	Cirrhose et carcinome h�patocellulaire : diagnostic et suivi biologique. 2017 , 2017, 64-71		
215	Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma. 2017 , 41, 289-293		15
214	NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 706-715	2.2	12
213	HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival. 2017 , 62, 2182-2192		12
212	Advances in management of hepatocellular carcinoma. 2017 , 29, 288-295		31
211	New concepts in embolotherapy of HCC. 2017 , 34, 58		42
210	Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore. 2017 , 24, 143-152		17
209	The diagnosis and treatment of hepatocellular carcinoma. 2017 , 34, 153-159		278
208	Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. 2017 , 18, 67		1
207	Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. 2017 , 86, 135-142		15
206	A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. 2017 , 49, 1273-1279		3

205 Hepatocellular Carcinoma: Epidemiology, Basic Principles of Treatment, and Clinical Data. **2017**, 149-178

204 Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. **2017**, 6, 2017-2033 12

203 Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. **2017**, 15, 197-204 19

202 State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma. **2017**, 13, 1437-1448 22

201 Radiation Therapy for Liver Tumors. **2017**,

200 Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma. **2017**, 42, 34-39 11

199 Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. **2017**, 72, 141-149 9

198 Major Liver Resection for Large and Locally Advanced Hepatocellular Carcinoma. **2017**, 79, 326-331 4

197 Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. **2017**, 15, 746-755.e4 23

196 Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. **2017**, 27, 1448-1458 22

195 Hepatocellular Carcinoma. **2017**, 977-988

194 Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. **2017**, 6, 313-324 14

193 Tumors of the liver. **2017**, 1272-1298.e7

192 The importance of a multidisciplinary approach to hepatocellular carcinoma. **2017**, 10, 95-100 32

191 Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. **2018**, 6, 175-188 10

190 Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. **2017**, 4, 93-103 38

189 How admissions to various medical specialty divisions determines the outcome of patients with hepatocellular carcinoma: results from a retrospective study in a large hospital of northwest China. **2017**, 13, 545-553 2

188 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. **2018**, 69, 182-236 3196

187	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018 , 68, 723-750	11.2	1650
186	New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. 2018 , 117, 1540-1547		34
185	Tumours and Tumour-like Lesions of the Liver. 2018 , 780-879		8
184	Prognostic value of pretreatment PET/CT lean body mass-corrected parameters in patients with hepatocellular carcinoma. 2018 , 39, 564-571		1
183	Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. 2018 , 91, 20170436		5
182	Traitement chirurgical du carcinome hépatocellulaire dans le cadre et en dehors des indications de Barcelone dans un centre de moyen volume. 2018 , 155, 278-285		
181	Liver Cancers. 2018 , 100-116		
180	Radiofrequency ablation versus surgical resection for multiple HCCs meeting the Milan criteria: propensity score analyses of 10-year therapeutic outcomes. 2018 , 73, 676.e15-676.e24		7
179	Surgical management of hepatocellular carcinoma within and beyond BCLC indications in a middle volume center. 2018 , 155, 275-282		5
178	Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. <i>Hepatology</i> , 2018 , 68, 977-993	11.2	90
177	Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. 2018 , 226, 1147-1159		8
176	Intraoperative ultrasound for prediction of hepatocellular carcinoma biological behaviour: Prospective comparison with pathology. 2018 , 38, 312-320		9
175	Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. 2018 , 38, 321-330		27
174	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. 2018 , 117, 381-403		58
173	Quality of life as a prognostic factor for survival in hepatocellular carcinoma. 2018 , 38, 885-894		14
172	Comparison of conservative treatment versus transcatheter arterial embolisation for the treatment of spontaneously ruptured hepatocellular carcinoma. 2018 , 83, e311-e318		1
171	A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy. 2018 , 15, 415-424		2
170	Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?. 2018 , 9, 750-761		10

169	A new risk score based on twelve hepatocellular carcinoma-specific gene expression can predict the patients prognosis. 2018 , 10, 2480-2497	13
168	Albi Score as a Predictor of Survival in Patients with Compensated Cirrhosis Resected for Hepatocellular Carcinoma: Exploratory Evaluation in Relationship to Palbi and Meld Liver Function Scores. 2018 , 57, 292-300	2
167	Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/Twist signaling pathway. 2018 , 16, 5299-5308	18
166	Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. 2018 , 24, 2348-2362	59
165	The prognostic value of prognostic nutritional index in hepatocellular carcinoma patients: A meta-analysis of observational studies. 2018 , 13, e0202987	24
164	Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. 2018 , 7, 2816	11
163	Liver chemoembolization of hepatocellular carcinoma using TANDEM microspheres. 2018 , 14, 2761-2772	8
162	Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. 2018 , 47, 585-602	17
161	Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. 2018 , 13, e0194922	11
160	Long-term outcomes in elderly patients with resectable large hepatocellular carcinoma undergoing hepatectomy. 2018 , 27, 595-601	6
159	Hepatocellular Carcinoma. 2018 , 529-543	1
158	Ontology-Based Approach for Liver Cancer Diagnosis and Treatment. 2019 , 32, 116-130	6
157	Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification. 2019 , 26, 3693-3700	57
156	A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomy. 2019 , 39, 55	16
155	IRC-SET 2018. 2019 ,	
154	Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?. 2019 , 8,	10
153	Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection. 2019 , 13, 715-725	4
152	Comparison of new prognostic systems for patients with resectable hepatocellular carcinoma: Albumin-Bilirubin grade and Albumin-Indocyanine Green Evaluation grade. 2019 , 49, 1218-1226	4

151	Interleukin-6 as a biomarker in patients with hepatobiliary cancers. 2019 , 10, 537-545	2
150	Is there a sex difference in postoperative prognosis of hepatocellular carcinoma?. 2019 , 19, 250	7
149	Endoscopic Ultrasound for the Diagnosis and Staging of Liver Tumors. 2019 , 29, 339-350	7
148	Comparative liver function models for ruptured hepatocellular carcinoma: A 10-year single center experience. 2019 , 42, 874-882	5
147	Staging of Biliary and Primary Liver Tumors: Current Recommendations and Workup. 2019 , 28, 663-683	4
146	"Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study". 2019 , 19, 229	2
145	Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. 2019 , 46, 661-668	4
144	Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. 2019 , 8, 78-91	27
143	The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma. 2019 , 120, 4140-4146	31
142	Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. 2020 , 22, 383-390	6
141	The Critically Ill Cirrhotic Patient. 2020 ,	
140	Impact of Surveillance in Chronic Hepatitis B Patients on Long-Term Outcomes After Curative Liver Resection for Hepatocellular Carcinoma. 2020 , 24, 1987-1995	2
139	Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting. 2020 , 196, 334-348	6
138	Epidemiology of Liver Cancer in Latin America: Current and Future Trends. 2020 , 40, 101-110	3
137	Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines. 2020 , 27, 866-874	21
136	Review article: new therapeutic interventions for advanced hepatocellular carcinoma. 2020 , 51, 78-89	47
135	Protocolo diagnóstico de las lesiones ocupantes de espacio hepáticas en hígado cirrótico. 2020 , 13, 688-692	
134	The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma. 2021 , 23, 1061-1071	5

133	Microwave ablation shows similar survival outcomes compared with surgical resection for hepatocellular carcinoma between 3 and 5 cm. 2020 , 37, 1345-1353		1
132	Protocolo de estadificación y asignación de tratamiento en el carcinoma hepatocelular. Algoritmo BCLC. 2020 , 13, 703-706		
131	Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence. 2020 , 12, 3721-3729		11
130	Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. 2020 , 30, 4150-4163		13
129	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. 2020 , 19, 546-569		6
128	Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. 2020 , 32, 5		51
127	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 1033-1050	4.9	8
126	Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. 2020 , 8, 444-452		5
125	Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. 2020 , 107, 854-864		27
124	Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS -applied prediction model. 2020 , 111, 1084-1092		7
123	Albumin-Bilirubin Score vs Model for End-Stage Liver Disease in Predicting Post-Hepatectomy Outcomes. 2020 , 230, 637-645		21
122	Use of Gadoxetic Acid-enhanced Liver MRI and Mortality in More than 30 000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis. 2020 , 295, 114-124		5
121	Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. 2020 , 27, 2321-2331		26
120	Liver Resection for Hepatocellular Carcinoma and the Barcelona Clinic Liver Cancer Criteria: Is It Time to Push the Limits?. 2020 , 27, 2122-2124		1
119	Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma. 2021 , 26, e445-e453		6
118	Prediction of tumor recurrence by Ffetoprotein model after curative resection for hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 660-666	3.6	8
117	Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. 2021 , 406, 75-86		5
116	Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC). 2021 , 31, 1630-1641		1

115	An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. 2021 , 55, 130-143		2
114	A Machine Learning Approach Yields a Multiparameter Prognostic Marker in Liver Cancer. 2021 , 9, 337-347		3
113	External Validation of Six Liver Functional Reserve Models to predict Posthepatectomy Liver Failure after Major Resection for Hepatocellular Carcinoma. 2021 , 12, 5260-5267		1
112	Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias. 2021 , 16, e0249194		0
111	Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. 2021 , 8, 253-261		2
110	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021 , 13,	6.6	7
109	An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. 2021 , 48, 3656-3665		1
108	Micronvasive behaviour of single small hepatocellular carcinoma: which treatment?. 2021 , 73, 1359-1369		4
107	Quality of Life after Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Compared with Transcatheter Arterial Chemoembolization alone. 2021 , 22, 1255-1261		0
106	A machine-learning modified CART algorithm informs Merkel cell carcinoma prognosis. 2021 , 62, 323-330		0
105	Inspecting Management Strategies of Hepatocellular Carcinoma in a Tertiary Centre in Western Rajasthan. 2021 , 10, 1314-1318		
104	Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan. 2021 , 4, e2114680		4
103	Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma. 2021 , 100, e27000		0
102	Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma. 2021 , e1749		0
101	The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	3
100	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. 2021 , 9,		9
99	Natural History and Stages of Cirrhosis. 2014 , 15-28		4
98	Viral Hepatitis and Hepatocellular Carcinoma. 2009 , 431-447		2

97	Staging of Hepatocellular Carcinoma. 2011 , 69-80	1
96	Staging of Hepatocellular Carcinoma. 2012 , 161-175	1
95	Hepatocellular Carcinoma Surveillance and Staging. 2019 , 27-51	2
94	Transarterial therapies for hepatocellular carcinoma. 2013 , 190, 195-206	13
93	Hepatocellular Carcinoma. 2011 , 489-501	2
92	Tumors and Cysts of the Liver. 2010 , 1569-1592.e6	2
91	A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. 2013 , 8, e68203	10
90	A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization. 2013 , 8, e82225	19
89	Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. 2014 , 9, e88182	31
88	Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH). 2015 , 10, e0138374	1
87	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. 2016 , 11, e0165722	19
86	Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. 2017 , 12, e0180408	21
85	Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. 2017 , 12, e0185198	15
84	Hepatocellular carcinoma surveillance: Eastern and Western perspectives. 2019 , 38, 191-199	8
83	SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. 2017 , 8, 68381-68392	45
82	Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. 2014 , 5, 9425-43	61
81	Applying of pretreatment extent of disease system in patients with hepatocellular carcinoma after curative partial hepatectomy. 2016 , 7, 30408-19	2
80	Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. 2011 , 17, 113-9	22

79	Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results. 2011 , 17, 120-9	4
78	Current management strategy of hepatocellular carcinoma. 2009 , 15, 3210-6	111
77	Staging systems of hepatocellular carcinoma: a review of literature. 2014 , 20, 4141-50	73
76	Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective. 2017 , 23, 4054-4063	11
75	Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. 2020 , 26, 393-403	16
74	Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. 2019 , 34, 1223-1232	6
73	Impact of Malnutrition on Nutritional and Non Nutritional Factors in End Stage Liver Disease. 2017 , 9, 77-88	3
72	Cytochrome P450 family members are associated with fast-growing hepatocellular carcinoma and patient survival: An integrated analysis of gene expression profiles. 2019 , 25, 167-175	13
71	Extrahepatic Feeding of HCC Limits the Use of TACE? Evidences from Literature and Clinical Experience. 2013 , 04, 413-419	2
70	Update in management of hepatocellular carcinoma in Eastern population. 2015 , 7, 1562-71	19
69	Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. 2015 , 7, 2274-91	39
68	Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. 2015 , 5, 19-25	3
67	Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. 2012 , 32, 174-99	19
66	International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. 2014 , 33, 481-91	18
65	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 2021 , 19, 541-565	74
64	Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand. 2014 , 15, 3567-70	40
63	Health-related quality of life of patients with intermediate hepatocellular carcinoma after liver resection or transcatheter arterial chemoembolization. 2015 , 16, 4451-6	16
62	Diagnosis and Evaluation of Hepatocellular Carcinoma. 2021 , 1-22	

- 61 Clinical outcomes of patients with two small hepatocellular carcinomas. **2021**, 13, 1439-1449
- 60 Hepatocellular Carcinoma. **2006**, 1109-1131
- 59 Malignome des Gastrointestinaltrakts. **2007**, 573-690
- 58 Carcinoma hepatocelular. **2008**, 419-429
- 57 Modelos para definir receptores de alto riesgo y el momento del trasplante. **2008**, 30-43
- 56 Liver. **2008**, 943-961
- 55 Prognostic prediction in hepatocellular carcinoma: from art to science. **2008**, 42, 221-3 1
- 54 Pathologic Aspects of Hepatocellular Tumors. **2009**, 183-233
- 53 Staging. **2009**, 94-103
- 52 Malignant Tumors. **2010**, 1305-1350
- 51 Hepatocellular Carcinoma. 978-989
- 50 Surgical Options in Liver Cancers. 990-1005
- 49 Rival Scoring Systems: Do they Offer more?. 81-90
- 48 Comparative Performances of Staging Systems for Hepatocellular Cancer: Early HCC Considerations. 73-80
- 47 Staging of Hepatocellular Carcinoma, Hepatoblastoma, and Cholangiocarcinomas. **2016**, 1-19
- 46 Liver Cancer Among Asian Americans. **2016**, 233-248
- 45 Which Is the Better Predictor of Hepatic Reserve Prior to Liver Resection: MELD or the Child-Pugh Score?. *Difficult Decisions in Surgery: an Evidence-based Approach*, **2016**, 189-199 0
- 44 Current HCC Staging Systems: Their Uses and Limitations. **2016**, 425-442 3

43	Staging of Hepatocellular Carcinoma, Hepatoblastoma, and Cholangiocarcinomas. 2017 , 3501-3516		
42	Hepatocellular Carcinoma. 2018 , 668-692.e9		1
41	Updates in the Systemic Treatment of Hepatocellular Carcinoma. <i>Oncology & Hematology Review</i> , 2018 , 14, 76	0.1	
40	Diagnosis and Staging of Hepatocellular Carcinoma (HCC). 2019 , 67-82		1
39	Prognostic Biomarkers for Hepatocellular Carcinoma. 2019 , 1-8		
38	Liver Cancer. 2019 , 405-420		
37	The Management of Hepatocellular Carcinoma. 2020 , 237-271		0
36	Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study.		
35	The impact of HIV on hepatocellular cancer survival in Nigeria. <i>Tropical Medicine and International Health</i> , 2021 , 26, 335-342	2.3	2
34	Transarterial Chemoembolization with LC Bead LUMI followed by Stereotactic Body Radiation Therapy in Treatment of Hepatocellular Carcinoma.. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100830	3.3	
33	Interventional Radiological Management of Hepatocellular Carcinoma. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020 , 41, 484-487	0.2	
32	Caracterizaci3n, manejo y pron3stico de una cohorte de pacientes cirr3gicos con carcinoma hepatocelular. Hospital Pablo Tob3 Uribe 2012-2018. <i>Hepatolog3a</i> , 2020 , 134-144	0.1	0
31	Living Donor Liver Transplantation. 2006 , 547-558		
30	Current management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 153-61	0.7	70
29	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 1-24	0.7	5
28	Update on the Diagnosis and Treatment of Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2020 , 16, 506-516	0.7	3
27	The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients.. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022 , 20, 4	3.1	1
26	Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 33,	2.2	1

25	Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma.. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022 , 1	4.9	1
24	Predictors of Mortality in Patients with Advanced Cancer-A Systematic Review and Meta-Analysis.. <i>Cancers</i> , 2022 , 14,	6.6	1
23	S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. <i>Zeitschrift Fur Gastroenterologie</i> , 2022 , 60, e56-e130	1.6	0
22	S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms [Kurzversion 2.00] Juni 2021, AWMF-Registernummer: 032-053OL. <i>Zeitschrift Fur Gastroenterologie</i> , 2022 , 60, 81-107	1.6	
21	Terapias sisthnicas en carcinoma hepatocelular: secuencia de tratamientos. <i>Hepatologia</i> , 2022 , 57-71	0.1	
20	Updates on the staging and treatment of hepatocellular carcinoma. 2022 , 307-319		
19	Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy.. <i>OncoTargets and Therapy</i> , 2021 , 14, 5521-5532	4.4	3
18	The Prognostic Values of Neutrophil-to-lymphocyte Ratio and Platelet-to-Lymphocyte Ratio at Baseline in Predicting the In-hospital Mortality in Black African Patients with Advanced Hepatocellular Carcinoma in Palliative Treatment: A Comparative Cohort Study.. <i>Hepatic Medicine: Evidence-Based Liver Disease</i> , 2021 , 13, 100-107	3.4	0
17	Partial hepatectomy vs. transcatheter arterial chemoembolization for multiple hepatocellular carcinomas of BCLC-B stage: A meta-analysis of high-quality studies.. <i>European Journal of Surgical Oncology</i> , 2022 ,	3.6	0
16	Liver (Hepatocellular) Cancer. 2022 , 247-257		
15	CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib. <i>Molecular Carcinogenesis</i> ,	5	2
14	Potential Candidates for Liver Resection in Liver-Confined Advanced HCC: A Chinese Multicenter Observational Study. <i>SSRN Electronic Journal</i> ,	1	
13	Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma. 2023 , 109-132		
12	Case report: Urgent liver pathologies: All in one. <i>Frontiers in Surgery</i> , 9,	2.3	
11	Localized Metastatic Recurrence of HCC following Distal Extremity Trauma: Bone Scintigraphy and Anatomicopathological Correlation.		
10	Impact of tumor burden score on timing and patterns of recurrence after curative-intent resection of hepatocellular carcinoma. 2022 ,		1
9	Diagnosis and Evaluation of Hepatocellular Carcinoma. 2022 , 27-48		0
8	Influence of ChildBugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study.		1

7	Treatment patterns for hepatocellular carcinoma in patients with Child-Pugh class B and their impact on survival: A Korean nationwide registry study.	2
6	Variations in Textbook Oncologic Outcomes After Curative-Intent Resection: Early Versus Intermediate Hepatocellular Carcinoma Based on Barcelona Clinic Liver Cancer Criteria and Child-Pugh Classification.	0
5	Impact of treatment-duration-ratio of traditional Chinese medicine on survival period of primary liver cancer: A real-world study. 2022 , e12358	0
4	Fibrosis-4 index, a predictor for prognosis of hepatocellular carcinoma patients after curative hepatectomy even in hepatitis B virus dominant populations. 2023 , 104, 195	0
3	Tumours and Tumour-Like Lesions. 2024 , 842-946	0
2	S3-Leitlinie Diagnostik und Therapie biliärer Karzinome. 2023 , 61, 420-440	0
1	S3-Leitlinie Diagnostik und Therapie biliärer Karzinome (Langversion). 2023 , 61, e92-e156	0